Comparative Pharmacology
Head-to-head clinical analysis: NAPROXEN SODIUM versus ONMEL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NAPROXEN SODIUM versus ONMEL.
NAPROXEN SODIUM vs ONMEL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Non-selective cyclooxygenase (COX-1 and COX-2) inhibitor, reducing prostaglandin synthesis.
ONMEL (omacetaxine mepesuccinate) inhibits protein synthesis by binding to the 80S ribosome and interfering with chain elongation, leading to apoptosis in leukemic cells.
220-550 mg orally twice daily; maximum 1375 mg/day.
50 mg orally twice daily for 14 days
None Documented
None Documented
12–17 hours (terminal); allows twice-daily dosing; prolonged in elderly and renal impairment
Terminal half-life 40–60 hours (mean 50 hours); allows once-daily dosing for systemic antifungal therapy.
Renal: 95% (as unchanged drug, conjugated naproxen, and 6-O-desmethyl naproxen); Fecal: <5%
Primarily hepatic metabolism via CYP3A4; <1% excreted unchanged in urine; >90% eliminated as metabolites in bile and feces.
Category D/X
Category C
NSAID
NSAID